Shoushu Jiao, M.D., University of Wisconsin: Based upon reports from the University of Wisconsin as well as information obtained by the Office of Research Integrity (ORI) during its oversight review, ORI found that Dr. Jiao, former Research Associate, Department of Pediatrics, University of Wisconsin, engaged in scientific misconduct by falsifying and creating laboratory records while conducting biomedical research. The data in these records were reported in a National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH) grant application to support a request for Public Health Service (PHS) funding. Based on the factual findings in the reports, the following article has been retracted: Jiao, S., Gurevich, V., & Wolff, J.A. ''Long-term correction of rat model of Parkinson's disease by gene therapy.'' *Nature* 362:450–453, 1993.

Dr. Jiao has entered into a Voluntary Exclusion Agreement with ORI in which he has voluntarily agreed:

(1) To exclude himself from serving in any advisory capacity to PHS, including but not limited to service on any PHS advisory committee, board, and/or peer review committee, or as a consultant for a period of four (4) years, beginning on August 8, 1997.

(2) To exclude himself from any contracting or subcontracting with any agency of the United States Government and from eligibility for, or involvement in, nonprocurement transactions (e.g., grants and cooperative agreements) of the United States Government as defined in 45 CFR part 76 (Debarment Regulations) for a period of three (3) years, beginning on August 8, 1997; and

(3) That any institution that submits an application for PHS support for a research project on which Dr. Jiao's participation is proposed, uses him in any capacity on PHS supported research, or submits a report of PHS-funded research in which he is involved must concurrently submit a plan for supervision of his duties to the funding agency for approval for a period of one (1) year following the three (3) year exclusion. The supervisory plan must be designed to ensure the scientific integrity of Dr. Jiao's research contribution. The institution also must submit a copy of the supervisory plan to ORI.

FOR FURTHER INFORMATION CONTACT: Acting Director, Division of Research Investigations, Office of Research Integrity, 5515 Security Lane, Suite 700, Rockville, MD 20852, (301) 443–5330.

Chris B. Pascal,

Acting Director, Office of Research Integrity.

[FR Doc. 97–22082 Filed 8–19–97; 8:45 am]

BILLING CODE 4160–17–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary

Findings of Scientific Misconduct

AGENCY: Office of the Secretary, HHS.

ACTION: Notice.

SUMMARY: Notice is hereby given that the Office of Research Integrity (ORI) has made a final finding of scientific misconduct in the following case:

Jill A. London, Ph.D., University of Connecticut Health Center: Based upon a report from the University of Connecticut Health Center as well as information obtained by the Office of Research Integrity (ORI) during its oversight review, ORI found that Dr. London, former Assistant Professor, Department of Biostructure and Function, School of Dental Medicine, University of Connecticut Health Center, engaged in scientific misconduct by intentionally falsifying data in conjunction with applying for and reporting research supported by the National Institute of Neurological Disorders and Stroke (NINDS) and the National Institute on Deafness and Other Communication Disorders (NIDCD), National Institutes of Health (NIH).

Specifically, ORI found that Dr. London's grant applications and articles contained numerous falsifications, including:

(1) Figures 6, 7, and 8 in a paper (London, J.A. & Cohen, L.B. ''High time resolution, multi-site optical measurement of vertebrate somatosensory cortex during epileptiform discharges and vertebrate gustatory cortex.'' *Optical Methods in Neurobiology*, pp. 61–78, 1988.) prepared for the 11th Annual Meeting of the European Neuroscience Association (hereafter referred to as the European Neuroscience paper) that cited support by NINDS, NIH grants R01 NS08437 and P01 NS16993;

(2) Figure 1A in a paper (London, J.A., ''Optical recording of activity in the hamster gustatory cortex elicited by electrical stimulation of the tongue.'' *Chemical Senses* 15:137–143, 1990.) that cited support by NINDS, NIH grants R01 NS08437 and P01 NS16993; Figure 1A was found to be very similar or identical to Figure 7 of the European Neuroscience paper in #1 above;

(3) Figures 10 to 13 in grant application 2 P50 DC00168–14, ''Connecticut Chemosensory Clinical Research Center,'' submitted to NIDCD, NIH on January 28, 1994; these figures also appear as Figures 4 to 7 in grant application 2 P50 DC00168–14A1, submitted to NIDCD, NIH on September 28, 1994;

(4) Figures 2, 8, and 9 in grant application 1 R01 DC01752–01, ''Optical recording of hamster gustatory cortex activity,'' submitted to NIDCD, NIH on January 29, 1992; these figures were the same as Figures 11, 12, and 13, respectively, in grant application 2 P50 DC00168–14 (see #3 above);

(5) Figures supplied for Figures 1 and 3 in grant application 1 F32 NS09601–01, ''Modular response patterns in hamster gustatory cortex,'' submitted to NINDS, NIH on August 3, 1993; these figures were the same as Figures 10 and 11, respectively, in grant application 2 P50 DC00168–14 (see #3 above);

(6) Figure 3 of a handout that Dr. London provided during an NIH site visit on April 25, 1994, conducted in conjunction with the review of grant application 2 P50 DC00168–14; the top and bottom portions of Figure 3 of the site visit handout were very similar or identical to Figures 6 and 7, respectively, of the European Neuroscience paper (see #1 above), and approximately 115 of the 125 traces appearing in each of the figures showed identities, with one or two ''active'' traces being identical;

(7) Figures 1, 2, and 3 in a paper (London, J.A. & Wehby, R.G. ''Classification of inhibitory responses of hamster gustatory cortex.'' *Brain Research* 666:270–274, 1994.) that cited support by NIDCD, NIH grants P50 DC00168 and T32 DC00025; and

(8) Nine figures included in a manuscript (London, J.A. & Wehby, R.G. ''Excitatory neural responses in the hamster gustatory cortex.'' Submitted to *Brain Research*, 1996.) that cited support by NIDCD, NIH grants P50 DC00168 and T32 DC00025. Dr. London has accepted the ORI finding and has entered into a Voluntary Exclusion Agreement with ORI in which she has voluntarily agreed, for a period of five (5) years, beginning August 8, 1997:

(1) To exclude herself from any contracting or subcontracting with any agency of the United States Government and from eligibility for, or involvement in, nonprocurement transactions (e.g., grants and cooperative agreements) of the United States Government as defined in 45 C.F.R. Part 76 (Debarment Regulations); and

(2) To exclude herself from serving in any advisory capacity to the Public Health Service (PHS), including but not limited to service on any PHS advisory committee, board, and/or peer review committee, or as a consultant. Dr. London is required to submit a letter to

- *Chemical Senses* requesting a retraction of the following article: London, J.A. ''Optical recording of activity in the hamster gustatory cortex elicited by electrical stimulation of the tongue.'' *Chemical Senses* 15:137–143, 1990;
- *Brain Research* requesting a retraction of the following article: London, J.A., & Wehby, R.G. ''Classification of inhibitory responses of the hamster gustatory cortex.'' *Brain Research* 666:270–274, 1994; and
- *Optical Methods in Neurobiology* requesting a retraction of Section V, Results—Hamster of the following article: London, J.A., & Cohen, L.B. ''High time resolution, multi-site optical measurement of vertebrate somatosensory cortex during epileptiform discharges and vertebrate gustatory cortex.'' *Optical Methods in Neurobiology*, pp. 61–78, 1988, prepared for the 11th Annual Meeting of the European Neuroscience Association.

FOR FURTHER INFORMATION CONTACT: Acting Director, Division of Research Investigations, Office of Research Integrity, 5515 Security Lane, Suite 700, Rockville, MD 20852, (301) 443–5330.

Chris B. Pascal,

Acting Director, Office of Research Integrity.

[FR Doc. 97–22081 Filed 8–19–97; 8:45 am]

BILLING CODE 4160–17–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 97F–0301]

Ube Industries (America), Inc.; Filing of Food Additive Petition; Correction

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice; correction.

SUMMARY: The Food and Drug Administration (FDA) is correcting a notice that appeared in the **Federal Register** of July 21, 1997 (62 FR 39003). The document announced that Ube Industries (America), Inc., filed a petition proposing that the food additive regulations be amended to change the melting point range specifications for Nylon 6/66 resins intended for use in contact with food. The document published with an incorrect docket number. This document corrects that error.

FOR FURTHER INFORMATION CONTACT: Vir D. Anand, Center for Food Safety and Applied Nutrition (HFS–215), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202–418–3081.

In FR Doc. 97–19127, appearing on page 39003 in the **Federal Register** of Monday, July 21, 1997, the following correction is made:

1. On page 39003, in the first column, Docket No. ''97N–0301'' is corrected to read ''97F–0301''.

Dated: August 13, 1997.

William K. Hubbard,

Associate Commissioner for Policy Coordination.

[FR Doc. 97–22091 Filed 8–19–97; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public.

Name of Committee: Anesthetic and Life Support Drugs Advisory Committee.

General Function of the Committee: To provide advice and recommendations to the agency on FDA regulatory issues.

Date and Time: The meeting will be held on September 17, 1997, 8 a.m. to 5 p.m.

Location: Gaithersburg Hilton, Grand Ballroom, 620 Perry Pkwy., Gaithersburg, MD.

Contact Person: Karen M. Templeton-Somers or Robin M. Spencer, Center for Drug Evaluation and Research (HFD–21), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–443–5455, or FDA Advisory Committee Information Line, 1–800–741–8138 (301–443–0572 in the Washington, DC area), code 12529. Please call the Information Line for up-to-date information on this meeting.

Agenda: The committee will hear presentations and discuss data submitted regarding new drug application (NDA) 20–747, Actiq™ (oral transmucosal fentanyl citrate, drug matrix on a handle), Anesta Corp., for the management of chronic pain, particularly breakthrough pain, in patients who are already receiving and are tolerant to opioid therapy.

Procedure: Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by September 4, 1997. Oral presentations from the public will be scheduled between approximately 8 a.m. and 8:30 a.m. and 3 p.m. and 3:30 p.m. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before September 4, 1997, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: August 14, 1997.

Michael A. Friedman,

Deputy Commissioner for Operations.

[FR Doc. 97–22090 Filed 8–19–97; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public.

Name of Committee: Blood Products Advisory Committee.

General Function of the Committee: To provide advice and recommendations to the agency on FDA regulatory issues.

Date and Time: The meeting will be held on September 18, 1997, 8 a.m. to 5:30 p.m., and September 19, 1997, 8 a.m. to 4 p.m.

Location: Quality Suites Hotel, Potomac Rooms I, II, and III, Three Research Ct. (off Shady Grove Rd.), Rockville, MD.

Contact Person: Linda A. Smallwood, Center for Biologics Evaluation and Research (HFM–350), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852, 301–827–3514, or FDA Advisory Committee Information